Onyx Biotec is a contract manufacturer that turns other drug companies’ formulas into sterile, ready-to-sell medicine - it does not own the brands patients see. Founded in 2005 as a private venture and listed on the NSE’s small-company platform in late 2024, the company has built its business one factory at a time, starting with a single water-for-injection line and adding a second plant for cephalosporin antibiotics only when the first was already supplying India’s largest pharma houses. The recurring approach is to install a dedicated production block, secure a regulatory licence, and then fill it with long-term supply contracts from name-brand customers - capacity follows commitment.
Business segments
Two manufacturing engines, each a dedicated plant making a distinct product family - the original sterile-water ampoule line that built the customer base, and a newer antibiotics facility that is now winning export approvals and orders from top-tier Indian pharma groups.
1. Sterile water ampoules: the foundation contract that pays the bills
A single plant running six form-fill-seal machines churns out sterile-water ampoules under multi-year supply deals with some of India’s biggest drug companies.
- One product, one process - Unit-1 makes Sterile Water for Injections (SWFI) ampoules using Form-Fill-Seal (FFS) technology, a method that moulds the plastic container, fills it and seals it in one continuous, sterile step, so there is no human handling of the open product.
- The customer list is the moat - it already supplies Aristo, Mankind, Dr. Reddy’s, Sun Pharma and Macleods, and has locked in a five-year manufacturing agreement with Innova Captab, which means revenue visibility stretches years ahead.
- Upgrading to bigger bags - the IPO raised money to retrofit this same unit to produce large-volume parenterals (IV fluids in bigger containers), so the plant can sell a higher-value product to the same hospital-facing customers.
2. Dry-powder antibiotics: the growth engine built on the first plant’s cash flows
A second, newer facility makes cephalosporin-class dry-powder injections and syrups, and it has just begun converting customer audits into purchase orders and export licences.
- Built after the first plant was stable - Unit-2 started manufacturing only in 2023, thirteen years after Unit-1, and is located in the same Solan district of Himachal Pradesh, so the company could replicate its regulatory and logistics playbook.
- Dry powder, not just water - this plant makes dry-powder injections and dry-powder syrups in the cephalosporin range, a family of antibiotics that are sensitive to moisture and need a strictly controlled dry environment to remain stable.
- Regulatory credentials are the entry ticket - Unit-2 received a WHO-GMP certificate from India’s national drug regulator (CDSCO) in May 2024, and its dry-injection line has since been cleared for export to the Democratic Republic of Congo, opening a market beyond India.
- Orders follow audits - Mankind Pharma audited the plant, and its subsidiary Mankind Prime Labs then placed an order worth roughly ₹6 crore for dry-powder injection manufacturing; a separate agreement with Galpha Laboratories adds another committed customer, so the plant is filling its capacity through the same contract-manufacturing model that Unit-1 proved.
- Adding speed at the packaging end - part of the IPO proceeds is earmarked for a high-speed cartooning packaging line at Unit-2, which will let the plant box finished vials faster and handle larger batch sizes without a packaging bottleneck.